Managing Myeloma
- 2011-12-19 - ASH 2011 Multiple Myeloma Update – Day Three Afternoon: Carfilzomib And Pomalidomide -- The Myeloma Beacon
- 2011-12-17 - MLN9708, “Son of Bortezomib,” Shows Promising Initial Results In Multiple Myeloma (ASH 2011) -- The Myeloma Beacon
- 2011-12-14 - Vorinostat Shows Activity as Salvage in Multiple Myeloma -- Medscape Today
- 2011-12-14 - ASH: New Multiple Myeloma Drug Shows Early Promise -- Medpage Today
- 2011-12-13 - ASH 2011 Multiple Myeloma Update – Day Three Morning: Current Therapies -- The Myeloma Beacon
- 2011-12-13 - Multiple Myeloma Research Consortium (MMRC) Presents New Data Affirming Success in Accelerating Drug Development Timelines -- Market Watch
- 2011-12-12 - ASH 2011 Multiple Myeloma Update – Day Two -- The Myeloma Beacon
- 2011-12-12 - New Insight Into Drug Action in Multiple Myeloma -- Medscape Today News
- 2011-12-12 - Peptide 'cocktail' elicits immune response to multiple myeloma -- EurekAlert
- 2011-12-12 - Phase II Study Evaluates Clinical Benefit of Pomalidomide in Heavily Pre-Treated Patients with Multiple Myeloma -- Business Wire
- 2011-12-11 - Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting -- PR Newswire
- 2011-12-11 - ASH 2011 Multiple Myeloma Update – Day One -- The Myeloma Beacon
- 2011-12-11 - ARRY-520 Demonstrates Durable Single-Agent Activity in Patients with Advanced Multiple Myeloma -- News Wire
- 2011-12-11 - Beacon Breaking News – Carfilzomib To Get Standard, Not Priority, FDA Review -- The Myeloma Beacon
- 2011-12-10 - Second-Line Bortezomib + Dexamethasone Active in Patients with Multiple Myeloma -- Monthly Prescriber Reference